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ABSTRACT
Background. Colorectal cancer (CRC) is a leading cause
of cancer-related death worldwide. Growing evidence
indicates that tumor-initiating cells (TICs) are responsible
for tumor growth and progression. Conventional
chemotherapeutics do not sufficiently eliminate TICs,
leading to tumor relapse. We aimed to gain insight into TIC
biology by comparing the transcriptome of primary TIC
cultures and their normal stem cell counterparts to uncover
expression differences.
Methods. We established colonosphere cultures derived
from the resection of paired specimens of primary tumor
and normal mucosa in patients with CRC. These colono-
spheres, enriched for TICs, were used for differential
transcriptome analyses to detect new targets for a TIC-
directed therapy. Effects of target inhibition on CRC cells
were studied in vitro and in vivo.
Results. Pathway analysis of the regulated genes showed
enrichment of genes central to PI3K/AKT and Wnt-sig-
naling. We identified CD133 as a marker for a more
aggressive CRC subpopulation enriched with TICs in
SW480 CRC cells in an in vivo cancer model. Treatment of
CRC cells with the selective AKT inhibitor MK-2206
caused a decrease in cell proliferation, particularly in the
TIC fraction, resulting in a significant reduction of the
stemness capacity to form colonospheres in vitro and to
initiate tumor formation in vivo. Consequently, MK-2206
treatment of mice with established xenograft tumors
exhibited a significant deceleration of tumor progression.
Primary patient-derived tumorsphere growth was signifi-
cantly inhibited by MK-2206.
Conclusion. This study reveals that AKT signaling is
critical for TIC proliferation and can be efficiently targeted
by MK-2206 representing a preclinical therapeutic strategy
to repress colorectal TICs.
Colorectal cancer (CRC) is the second most common
cancer worldwide.1 Although numerous improvements in
treatment modalities have been achieved, approximately
40 % of patients will still die from recurrent or metastatic
disease within 5 years.2 Consequently, conventional ther-
apeutic strategies are unable to eliminate all cancer cells.
CRC is a stem-cell-driven malignancy in which only a
small population of cells, simplified as tumor-initiating
cells (TICs), are able to initiate and sustain tumor growth.3
TICs are undifferentiated tumor cells with the exclusive
ability to self-renew and to generate the cellular hetero-
geneity of a tumor. TICs are more resistant to conventional
anticancer therapy and therefore may be the main cause of
treatment escape and tumor relapse.4–6
Initially, the TIC population in CRC was identified by
the presence of the surface marker CD133, which showed
an increased tumorigenic potential in xenografts of
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immunodeficient mice.7 Despite the description of some
surface markers, only an insufficient purity of TICs can be
achieved so far and their biology remains undefined.8
Hence, identifying the regulatory mechanisms and signal-
ing pathways involved in TICs, and developing targeted
therapy, might raise promising strategies in the treatment
of CRC.
Emerging data revealed PI3K/AKT/mTOR signaling
implicated in the progression of CRC and that components of
the mTOR pathway were overexpressed in CRC.9 In recent
studies, a new oral-specific AKT1/2/3 inhibitor, MK-2206,
provided in vitro and in vivo antitumor activity as a single
agent, as well as enhanced activity in combination with
conventional chemotherapeutics.10–13 In addition, MK-2206
has been shown to be safe in humans, with early evidence of
antitumor activity in clinical trials.14,15
The present study aimed to determine the phenotypic
and molecular differences between colonic TICs and their
normal colon stem cell counterparts. Transcriptome anal-
yses revealed that genes involved in AKT signaling are
enriched in the TIC cultures. Functional testing implicated
the selective AKT inhibitor MK-2206 as a potential ther-
apeutic for TIC-directed therapy in CRC.
METHODS
Patient Material
Human colon cancer and adjacent normal mucosa tissue
were obtained after surgical resection and characterization
by a pathologist. Tissue collection was approved by the
Ethics Committee of the University Hospital Frankfurt, and
after written consent had been received from all patients
involved in the study. Solid tissues were minced and dis-
sociated with 200 U/ml Collagenase type III, 100 U/ml
Dispase, and 100 U/ml DNase I (all Worthingtorn, USA)
in HBSS for 60–90 min at 37 C. Every 30 min the cell
suspension was subjected to MACS tissue dissociator for
40 s. Cells were filtered through sterile 70 lm nylon mesh
[Becton Dickinson (BD), Heidelberg, Germany], and con-
taminated red blood cells were removed by osmotic lysis.
Sphere Formation Assay
Isolated cells were suspended in serum-free DMEM/F12
(Gibco, Germany) supplemented with 20 ng/ml epidermal
growth factor and fibroblast growth factor, 2 % N2 sup-
plement (Life Technologies, Germany), 20 mmol/l
HEPES, and 50 U/ml penicillin/streptomycin at a density
of 50,000 cells (tumor) and 100,000 cells (normal) per well
in ultra-low-attachment 24-well plates (Corning, Ger-
many), as described by Kreso and O’Brien.16 Plates were
scored microscopically after 7 and 14 days.
Microarray Analysis
Expression analysis was performed using Genechip
Human Exon 1.0 ST. Array (Affymetrix, Santa Clara, CA,
USA). RNA was extracted from 14-day tumorspheres and
corresponding colonospheres from normal tissue using an
RNeasy Midi kit according to the manufacturer’s instruc-
tions. RNA quantity and quality were assessed using
Nanovue (GE Life Sciences, USA) and 2100 Bioanalyzer
(Agilent, USA), respectively. Only samples with a high
RNA integrity number (RIN: 8–10) were used for the
profiling. Genes with a twofold cut-off were then further
subdivided into functional categories and pathways with
the bioinformatics analysis resource DAVID (Database for
Annotation, Visualization and Integrated Discovery) of the
Laboratory of Immunopathogenesis and Bioinformatics.
Cell Culture
Human CRC cell lines SW480 and hematocrit (HCT)-
116 were cultured in McCoy’s 5a and CX-1 in MEM-Earls
containing 10 % FCS, 200 mM HEPES, 2 mmol L-glu-
tamine, 50 units/ml penicillin/streptomycin in 37 C
humidified atmosphere with 5 % CO2. All cell lines were
purchased from CLS Cell Lines Service GmbH, Eppel-
heim, Germany.
In Vitro Drug Treatment
MK-2206 (Selleckchem, Munich, Germany) and 5-flu-
orouracil (Sigma-Aldrich, Munich, Germany) were
dissolved in dimethyl sulfoxide (DMSO) and stored at
-20 C. 5000 SW480, HCT-116 and CX-1 cells per well
in 96-well plates were cultured with or without 5-fluo-
rouracil (10 lM) and combination treatment with or
without MK2206 (5 lM) for 24–72 h. Proliferation was
assessed using a 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay according to the
manufacturer’s instructions in pentaplicate. For apoptosis
and cell cycle assays, 25,000 cells per well were cultured in
24-well plates under the same treatment as previously
described. Apoptosis was determined 24 and 72 h after
treatment using AnnexinV/7AAD staining (BD, Germany),
according to the manufacturer’s instructions, after cells
were stained with anti CD133-PE. To determine the cell
cycle distribution, 48 and 72 h after treatment cells were
pulsed with bromodeoxyuridine (BrdU) for 8 h, stained
with anti-CD133-PE followed by fixation/permeabilization
and anti-BrdU and DNA content (7AAD) staining using an
FITC BrdU flow kit (BD, Germany), according to the
manufacturer’s instructions. The cells were analyzed on an
FACSCanto II (BD, Germany).
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The effect of treatment on tumorsphere formation was
investigated by sphere formation assay as described above.
Flow Cytometry and Cell Sorting
SW480 cells were detached with AccutaseTM (Sigma-
Aldrich, Germany) and incubated with a PE-conjugated
antibody to human CD133 (clone AC133/1 Miltenyi Bio-
tec, Bergisch Gladbach, Germany) or a mouse isotype
control. Stained cells were analyzed via a FACSCanto or
sorted via a FACSAria (BD, Germany).
In Vivo Xenograft Experiments
All animal experiments were approved by the local
authorities. NOD.Cg-PrkdcscidI12rgtm1Wjl/SzJ (NSG) or
NOD.CB17-Prkdcscid/J (non-obese diabetic/severe com-
bined immunodeficiency [NOD/SCID]) mice (Jackson
Laboratory, USA) were used at 6–8 weeks of age. Fluo-
rescence-activated cell sorting (FACS)-sorted SW480 cells
(CD133high, CD133?, CD133-) were resuspended 1:1 in
Matrigel (BD, Germany) and serum-free medium, and were
injected subcutaneously into the flank at 5 9 104 cells per
mouse. For the in vivo treatment, MK-2206 (100 mg/kg)
was administered orally three times a week when tumor
size reached 0.2–0.3 cm in diameter. Tumor growth was
measured twice weekly using a caliper, and mice were
sacrificed when tumor size reached a diameter of 1 cm.
Western Blot
Heat-denatured protein samples were separated using
SDS-PAGE and transferred to a PVDF membrane (GE
Healthcare, Germany) by electroblotting (Bio-Rad, Ger-
many). Blots were blocked with 10 % milk for 1 h and
incubated with primary antibodies against total Akt,
phosphoAkt, or phosphoRPS6 (all Cell Signaling Tech-
nology, Danvers, MA, USA) overnight at 4 C. Proteins
were detected with peroxidase-goat anti-mouse antibody
and ECL (GE Healthcare, Germany) on a Fusion FX7
imaging system (Vilber Lourmat, France). b-Actin (Sigma-
Aldrich, Germany) was used as the internal loading
control.
Statistical Analysis
Statistical analyses were performed using GraphPad
Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA).
The microarray data were statistically analyzed using a t
test, by ATLAS Biolabs GmbH.
RESULTS
Gene expression revealed upregulated AKT, P53, and
Wnt signaling in primary tumorspheres.
First, we aimed to determine changes in gene expression
patterns and regulated pathways in TICs. Therefore, we
compared the transcriptome of five paired samples con-
sisting of tumorsphere-initiating cells and corresponding
non-malignant colonosphere-forming cells from five dif-
ferent CRC patients. The spheres were derived from freshly
resected cancer tissue and corresponding normal colon
mucosa after a 14-day culture. FACS analysis showed a
strong enrichment of CD133? cells in spheres (82.7 ±
7.5 %) in comparison to monolayer culture (16.9 ± 11 %;
n = 6, data not shown). The differential expression anal-
ysis revealed 79 induced and 32 repressed genes in
tumorspheres in comparison to normal colonospheres
(Fig. 1a, b, and Electronic Supplementary Table 1). Well-
described genes that are involved in CRC progression were
upregulated in tumorspheres, such as MET and MACC1.17
Next, we included the differentially expressed genes in a
functional annotation analysis using the DAVID algorithm.
When classified according to function, genes regulating
‘immune response’, ‘duplication’ and ‘protease’ were most
frequently identified (Fig. 1c). Importantly, well-described
pathways associated with CRC progression, such as ‘Wnt
signaling’ (DKK, Axin, CCND1), ‘P53 signaling’ (PERP,
SERPINB5), and ‘colorectal cancer’, including AKT
(CCND1, TSC, Axin, MET) and transforming growth
factor (TGF)-b signaling, were also overrepresented in
tumorspheres (Fig. 1d) and were thus potential targets for a
TIC-directed therapy.
High CD133 expression demarcates an aggressive TIC
subset in colorectal cancer SW480 cells.
To further investigate the role of TIC biology, we
employed SW480 CRC cells, given that they are geneti-
cally similar to most sporadic CRCs. FACS analysis of the
CRC cell line SW480 revealed a differential surface
expression of the described TIC marker CD1337,18 that
allowed us to prospectively separate three subsets of cells,
CD133- (3 %), CD133? (95.5 %), and CD133high (1.5 %)
cells (Fig. 2a).
To confirm that CD133 is a marker of tumor initiation in
SW480 cells, all three subpopulations were prospectively
isolated via FACS based on their CD133 expression, and
subcutaneously inoculated in NSG mice to monitor tumor
formation. Indeed, CD133high cells caused the most robust
and rapid establishment of tumors, and the tumors pro-
gressed faster than tumors from the CD133? or CD133-
populations (Fig. 2b). These results identify an aggressive
TIC population in SW480 cells.
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Selective AKT Inhibition Diminishes Colonic Tumor-
Initiating Cells In Vitro
Next, we assessed the effect of AKT inhibition on TIC
activity and survival. To this aim, SW480 cells were
treated with MK-2206, a selective AKT1/2/3 inhibitor, for
72 h. MK-2206 treatment for 24 h inhibited AKT kinase
activity (Fig. 2c). To evaluate the consequences of AKT
inhibition on tumor cell growth, CRC cells were treated
with MK-2206, and their cell expansion was analyzed. At
10 lM, MK-2206 significantly reduced cell proliferation
after 72 h of treatment (Fig. 2d). Next, we were able to
demonstrate that MK-2206 significantly decreased the
amount of the CD133high subset after 72 h of treatment
(Fig. 2e), indicating that MK-2206 treatment specifically

























































































































































































FIG. 1 Transcriptome profiling revealed upregulated AKT, P53, and
Wnt signaling pathways in CRC spheres. Exon-array expression
analyses of matched CRC tumorspheres/corresponding normal
colonospheres from five different patients. a Heat map showing a
two-dimensional clustering of the top 100 regulated genes. b Venn
diagram of regulated genes, tumor versus normal (p\ 0.05, fold
change[2). c DAVID functional annotation. d Pathway analysis of
differentially expressed genes in tumorspheres. The top functions (c)
and main canonical pathways (d) with their corresponding p values
are shown. CRC colorectal cancer
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To further investigate whether the effects induced by
MK-2206 were evoked by apoptosis induction or cell cycle
inhibition, we determined AnnexinV/7AAD staining and
BrdU incorporation in SW480 cells treated for 72 h via
FACS, to simultaneously discriminate the various CD133-
expressing cell subsets. While MK-2206 did not induce
apoptosis within 72 h in the CD133? bulk population of
cancer cells, we observed enhanced apoptosis in the TIC-
enriched fraction after 24 and 72 h of treatment (Fig. 2f).
In addition to a selective effect on apoptosis in the TIC
fraction, we determined a dose-dependent cell cycle G1
arrest in the bulk of SW480 cells treated with MK-2206, as
assayed by the incorporation of BrdU during the S-phase of
the cell cycle (Fig. 2g). To ensure that our findings were
CD133 high CD133 high



























































































































































































































bFIG. 2 Selective AKT
inhibition by MK-2206
diminishes TIC activity and
survival in vitro. a Three
subpopulations in SW480 cells
based on CD133 expression.
Representative FACS blot. b
Tumor growth of 50,000
prospectively isolated CD133
subpopulations injected
subcutaneously in NSG (n = 4).
c–g SW480 cells were treated
with 1, 5, or 10 lM MK-2206
for the indicated times. c
Western blot analysis after 72 h
of treatment. d Cell
proliferation (MTT assay). e
Fold change of CD133high-
expressing cells detected via
FACS. f Early apoptotic cells
(AnnexinV?/7-AAD-) in
CD133 subpopulations
determined via FACS. (g) Cell
cycle phase distribution in
CD133? bulk cells detected via
BrdU incorporation. h
Tumorsphere formation in CRC
cell lines. Data are expressed as
mean and standard deviation.
*p\ 0.05; **p\ 0.01
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not restricted to one cell line, we performed the tumor-
sphere formation assay in two additional CRC cell lines to
functionally confirm the effect of AKT inhibition on TIC
activity. After 7 days in culture, the number of tumor-
spheres were significantly diminished by MK-2206, even at
low concentrations in all three cell lines (Fig. 2h). Taken
together, AKT inhibition with MK-2206 reduces CRC cell
proliferation and directly inhibits TIC survival and function
in vitro.
MK-2206 Potentiates the Effect of 5-Fluorouracil
Chemotherapy
To elucidate the antitumoral effect of MK-2206, we
analyzed its impact on CRC cell proliferation and tumor-
sphere formation when co-treated with the standard
chemotherapeutic drug 5-fluorouracil in CRC treatment.
The combined treatment of MK-2206 and 5-fluorouracil
caused a significant inhibition of cell proliferation com-
pared with 5-fluorouracil alone, indicating a synergistic
anticancer effect of both drugs on CRC cells (Fig. 3a).
We then investigated whether the combination therapy
would be effective in inhibiting TIC proliferation. MK-
2206 alone was highly effective in inhibiting tumorsphere
formation in SW480 cells, while a combined treatment
with 5-fluorouracil did not further increase this effect
(Fig. 3b). Furthermore, a single treatment with 5-fluo-
rouracil did not cause cell cycle arrest in TICs, whereas
MK-2206 alone and combined treatment with 5-
fluorouracil significantly induced G1 cell cycle arrest in
TIC-enriched fraction after 72 h (Fig. 3c). Although MK-
2206 showed a synergistic antitumor effect when combined
with 5-fluorouracil, MK-2206 alone was highly effective in
suppressing colon TIC activity.
Selective AKT Inhibition Reduces Tumor Initiation and
Growth In Vivo and Patient-Derived Tumorsphere
Formation
Since TIC activity can only be reliably determined by its
capacity to initiate tumor growth in vivo, we assessed the
potency of MK-2206 in a xenograft transplantation model.
Therefore, we pretreated SW480 cells with MK-2206 or
DMSO for 72 h in culture before we subcutaneously injected
equal numbers of living cells into NOD/SCID mice (Fig. 4a).
The treatment with MK-2206 significantly delayed tumor
formation and significantly reduced tumor growth (mean
tumor weight 0.32 g vs. 0.12 g; p\ 0.05) (Fig. 4b, c)
induced by the remaining cells after the pretreatment, sug-
gesting that MK-2206 selectively eliminates TICs.
To further demonstrate the anticancer effects of MK-
2206 in vivo, NOD/SCID mice with established SW480
tumor cell xenografts were treated with MK-2206 or
DMSO (control) (Fig. 4d). While the DMSO-treated mice
showed a successive increase in tumor growth, MK-2206
treatment resulted in an almost complete stagnation of
tumor size, leading to small tumors that were as equal in








































































































FIG. 3 Synergistic antitumoral effects
of 5-fluorouracil and MK-2206 in CRC.
a–c SW480, HCT and Cx-1 cells were
treated with either 5 lM MK-2206,
10 lM 5-fluorouracil, or in
combination. a Cell proliferation was
determined after 48 h (MTT assay). b
SW480 tumorspheres scored after
14 days of treatment. c Percentage of
CD133high-SW480 cells in G1 phase
after 72 h of treatment detected via an
8 h BrdU pulse. Data are expressed as
mean and standard deviation.
*p\ 0.05; **p\ 0.01 compared with
DMSO. CRC colorectal cancer, DMSO
dimethyl sulfoxide, HCT hematocrit, 5-
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In order to translate our results on MK-2206 activity
against TICs to primary CRC patients, tumorsphere cul-
tures derived from freshly isolated patient CRC tissue were
treated with MK-2206. After 7 and 14 days of treatment,
the number and diameter of formed tumorspheres were
significantly reduced by MK-2206 compared with the
DMSO control (Fig. 4g, h). These results suggest that AKT
inhibition effectively impacts on TIC activity and serves as
a treatment strategy against colorectal TICs.
DISCUSSION
In this study, we report the effectiveness of selective
AKT inhibition by MK-2206 on diminishing the
tumorigenic potential of CRC-intiating cells. Although
already highly effective alone, MK-2206 showed syner-
gistic anticancer effects on CRC cell proliferation with
conventional chemotherapeutics such as 5-fluorouracil.
Of note, the effects of AKT inhibition on TIC activity
could be determined in both mismatch repair proficient
(SW480) and deficient (HCT-116) CRC cells. Impor-
tantly, MK-2206 reduced tumorsphere formation in
cancer cells derived from primary patient specimens.
Similar to recent results, treatment with MK-2206 gen-
erated a significant deceleration in tumor progression
in vivo.19
mTOR/AKT signaling is essential in the progression of
CRC, and mTOR inhibition leads to a reduction of CRC
cell growth.8,9,20 Cai et al. identified mTOR high expres-
sion to be an independent risk factor for the prognosis of
CRC patients.21 An activation of mTOR signaling has been
detected in colon TICs.22,23 In concordance with these
reports, the present study detected an increased expression
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FIG. 4 AKT inhibition by MK-2206 reduces tumor initiation and
growth in xenografts and tumorsphere formation in primary patient
material. a SW480 cells were pretreated with 10 lM MK2206 for
72 h in vitro and, subsequently, 50,000 living cells were injected
subcutaneously (n = 8). b Tumor volumes over time. c Tumor weight
after 4 weeks. d Equal numbers of SW480 cells were injected
subcutaneously. Once the tumor reached 25 mm3, mice were
randomized into two groups and treated with MK-2206 (100 mg/kg,
three times/week) or DMSO (control) [n = 6]. e Tumor volumes
under treatment over time. f Tumor weight after 3 weeks of treatment.
g Tumor cells from primary CRC patient material were treated with
DMSO or MK-2206, and sphere formation was determined (n = 5
CRC patients). h Representative images of sphere formation. Scale
bar 200 lm. Data are expressed as mean and standard deviation.
*p\ 0.05; **p\ 0.01 compared with DMSO. DMSO dimethyl
sulfoxide, CRC colorectal cancer, NOD non-obese diabetic, SCID
severe combined immunodeficiency
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Few studies have investigated the effects of mTOR
inhibitors on colon TICs. In one study, treatment with
rapamycin and PP242 diminished sphere formation as well
as aldehyde dehydrogenase activity in vitro.21 However,
the authors did not perform sufficient functional experi-
ments to investigate the effect of mTOR inhibitors on the
tumorigenic potential of colon TICs. A second study pro-
posed the mTOR kinase inhibitor Torin-1 as a drug
candidate for CRC therapy as it inhibited survival of colon
TICs in vitro and slowed tumor progression in vivo.22
Similarly, Todaro et al. showed, that PI3K-inhibition by
BKM-120 reduced metastatic growth of CRC cells.23
Nevertheless, no further studies have been reported to
elucidate the effectiveness of Torin-1 in cancer or its safety
in patients. Furthermore, the authors did not assess the
effects of Torin-1 or BKM-120 on the tumor initiation
ability of TICs.
CONCLUSIONS
We achieved a significant reduction of the tumor growth
originating from TICs, both in vitro and in vivo, by
selective AKT inhibition with MK-2206. Given that AKT
is both an upstream activator of the mTOR complex 1 and a
downstream effector of the mTOR complex2,24 and its
overexpression is associated with resistance to
chemotherapy,25 it represents a critical target of this sig-
naling cascade. Therefore, selective AKT inhibition may
be superior to mTOR inhibitors in the treatment of CRC,
and represents a promising agent to prevent tumor relapse
by eliminating the TIC subset. Our data strongly encourage
further clinical testing of MK-2206 either alone or in
combination with conventional chemotherapeutics in CRC
patients.
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